Basic principles of immunotherapy

被引:1
作者
Schilling, Georgia [1 ]
Arnold, Dirk [1 ]
机构
[1] Asklepios Klin Altona, Asklepios Tumorzentrum, Paul Ehrlich Str 1, D-22763 Hamburg, Germany
来源
RADIOLOGE | 2020年 / 60卷 / 08期
关键词
Immunomodulation; Oncolytic virotherapy; Checkpoint inhibitors; Monoclonal antibodies; T-cell transfer; ONCOLYTIC VIRUSES; CANCER; BLINATUMOMAB; CHEMOTHERAPY; ADULTS;
D O I
10.1007/s00117-020-00720-3
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Immunotherapy for malignant diseases is defined as a systematic therapeutic approach that aims to target the individual's immune system to prevent the development of malignancies or to combat existing tumors. Nowadays, this includes various therapeutic approaches, such as immune checkpoint inhibitors, BiTEs (bispecific T-cell engagers), CAR T-cells (CAR: chimeric antigen receptors) and oncolytic viruses, which have not only different mechanisms of action and points of attack, but also have very different efficiencies in the treatment of solid and hematological malignancies. These approaches undoubtedly enrich the therapeutic portfolio in oncology-in palliative systematic therapy and also in the interaction with operative and ablative local therapeutic approaches.
引用
收藏
页码:682 / 686
页数:5
相关论文
共 22 条
[1]   Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy [J].
Achard, Carole ;
Surendran, Abera ;
Wedge, Marie-Eve ;
Ungerechts, Guy ;
Bell, John ;
Ilkow, Carolina S. .
EBIOMEDICINE, 2018, 31 :17-24
[2]   Bispecific T-Cell Engaging Antibodies for Cancer Therapy [J].
Baeuerle, Patrick A. ;
Reinhardt, Carsten .
CANCER RESEARCH, 2009, 69 (12) :4941-4944
[3]   Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer [J].
Bracci, L. ;
Schiavoni, G. ;
Sistigu, A. ;
Belardelli, F. .
CELL DEATH AND DIFFERENTIATION, 2014, 21 (01) :15-25
[4]  
CleanPNG, 2020, WAT CIRCL
[5]  
Coley WB, 1893, AM J MED SCI, V105, P487, DOI DOI 10.1097/00000441-189305000-00001
[6]   An overview of cancer immunotherapy [J].
Davis, ID .
IMMUNOLOGY AND CELL BIOLOGY, 2000, 78 (03) :179-195
[7]   Arming oncolytic viruses to leverage antitumor immunity [J].
de Gruijl, Tanja D. ;
Janssen, Axel B. ;
van Beusechem, Victor W. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (07) :959-971
[8]   Classification of current anticancer immunotherapies [J].
Galluzzi, Lorenzo ;
Vacchelli, Erika ;
Bravo-San Pedro, Jose-Manuel ;
Buque, Aitziber ;
Senovilla, Laura ;
Baracco, Elisa Elena ;
Bloy, Norma ;
Castoldi, Francesca ;
Abastado, Jean-Pierre ;
Agostinis, Patrizia ;
Apte, Ron N. ;
Aranda, Fernando ;
Ayyoub, Maha ;
Beckhove, Philipp ;
Blay, Jean-Yves ;
Bracci, Laura ;
Caignard, Anne ;
Castelli, Chiara ;
Cavallo, Federica ;
Celis, Estaban ;
Cerundolo, Vincenzo ;
Clayton, Aled ;
Colombo, Mario P. ;
Coussens, Lisa ;
Dhodapkar, Madhav V. ;
Eggermont, Alexander M. ;
Fearon, Douglas T. ;
Fridman, Wolf H. ;
Fucikova, Jitka ;
Gabrilovich, Dmitry I. ;
Galon, Jerome ;
Garg, Abhishek ;
Ghiringhelli, Francois ;
Giaccone, Giuseppe ;
Gilboa, Eli ;
Gnjatic, Sacha ;
Hoos, Axel ;
Hosmalin, Anne ;
Jaeger, Dirk ;
Kalinski, Pawel ;
Kaerre, Klas ;
Kepp, Oliver ;
Kiessling, Rolf ;
Kirkwood, John M. ;
Klein, Eva ;
Knuth, Alexander ;
Lewis, Claire E. ;
Liblau, Roland ;
Lotze, Michael T. ;
Lugli, Enrico .
ONCOTARGET, 2014, 5 (24) :12472-12508
[9]   Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia [J].
Goekbuget, Nicola ;
Dombret, Herve ;
Bonifacio, Massimiliano ;
Reichle, Albrecht ;
Graux, Carlos ;
Faul, Christoph ;
Diedrich, Helmut ;
Topp, Max S. ;
Brueggemann, Monika ;
Horst, Heinz-August ;
Havelange, Violaine ;
Stieglmaier, Julia ;
Wessels, Hendrik ;
Haddad, Vincent ;
Benjamin, Jonathan E. ;
Zugmaier, Gerhard ;
Nagorsen, Dirk ;
Bargou, Ralf C. .
BLOOD, 2018, 131 (14) :1522-1531
[10]  
Gong Michael C., 1999, Neoplasia (New York), V1, P123, DOI 10.1038/sj.neo.7900018